cumyl-pegaclone cumyl-pegaclone cumyl-pegaclone (sgt-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug. the gamma-carboline core structure seen in cumyl-pegaclone had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by bristol-myers squibb in 2001. cumyl-pegaclonelegal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) uk: under psychoactive substances act identifiers iupac name 2,5-dihydro-2-(1-methyl-1-phenylethyl)-5-pentyl-1h-pyridoindol-1-one cas number2160555-55-3pubchem cid134818034chemspider68003813uniicut2rv7eiqchemical and physical dataformulac25h28n2omolar mass372.5 g·mol−13d model (jsmol)interactive image smiles cc(c1=cc=cc=c1)(c)n2c=cc(n(ccccc)c3=c4c=cc=c3)=c4c2=o inchi inchi=1s/c25h28n2o/c1-4-5-11-17-26-21-15-10-9-14-20(21)23-22(26)16-18-27(24(23)28)key:awhwtkxmujlsrm-uhfffaoysa-n legal status sweden's public health agency classified cumyl-pegaclone as a narcotic substance, on january 18, 2019. in the united states, the dea has filed a notice for its intent to temporarily place cumyl-pegaclone into schedule i status starting on or after may 4th, 2023 for up to 2 years, during which it's possible the dea could file for permanent scheduling within those 2 years. if it's filed on may 4, 2023, and the dea does not file to permanent placement the temporary schedule i order will expire on may 4, 2025.